[button : interested : interested : CM135]
Breast cancer is the second leading cause of death worldwide, and it is not limited to women. Tamoxifen is considered the gold line treatment for estrogen receptor positive breast cancer.
However, this chemopreventive approach has been focused on individuals in the high-risk group and limits its clinical applications to intermediate- or lower-risk groups. In addition, tamoxifen treatment is associated with dose-related hepatotoxicity and nephrotoxicity and ultimately leads to poor quality of life for patients. Sulforaphane, a naturally occurring isothiocyanate derivative, has been investigated for its numerous potential biological activities, including anticancer effects. The aim of this hypothesis is to present tamoxifen in combination with the natural bioactive sulforaphane, both of which are incorporated into a novel lipid-based nanocarrier at a reduced dose, which would ultimately transport the cargo to the target site. In breast cancer, Sulphoraphane sensitizes estrogen receptors and improves the binding affinity of tamoxifen to these receptors, thereby potentiating the anti-cancer efficacy and reducing the off-site toxicity of tamoxifen. This zero-dimensional, dually loaded lipid carrier would be a valuable addition to current treatment regimens for the management of breast cancer.
Read the full article at:
https:// www.carnomed.sk/produkty/sulforafan-extra.htm
https:// www.carnomed.sk/produkty/sulforafan-extra-xl-pure-gold-edition.htm